Drug Profile
Human papillomavirus vaccine bivalent - Zydus Lifesciences
Alternative Names: Bivalent Human Papillomavirus (Types 16 L1 & 18 L1); HPV vaccine - Zydus LifesciencesLatest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Cancer vaccines; Papillomavirus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Human-papillomavirus-infections(In volunteers) in India (IM)
- 28 Oct 2019 No recent reports of development identified for research development in Human-papillomavirus-infections in Italy (IM)
- 08 Jan 2018 Cadila Healthcare completes a phase I trial in Human papillomavirus infections (In volunteers) in India (IM) (CTRI2017-05-008537)